Global Regenerative Medicine Market Outlook to 2026

0

DUBLIN, October 18, 2021 / PRNewswire / – The “Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunities, and Forecast 2021-2026” report has been added to ResearchAndMarkets.com offer.

The global regenerative medicine market has reached a value of 11.94 billion US dollars in 2020. Looking ahead, the market is expected to grow at a CAGR of 22.7% during 2021-2026. Bearing in mind the uncertainties of COVID-19, the analyst is continuously monitoring and evaluating the direct and indirect influence of the pandemic on different end-use sectors. This information is included in the report as a major contributor to the market.

Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. This involves the use of stem cells developed in the laboratory and implanted safely in the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative drugs are commonly used in a variety of clinical therapeutic procedures, including cell, immunomodulation, and tissue engineering therapies. They have potential for the effective treatment of various chronic diseases, such as Alzheimer’s disease, Parkinson’s disease and cardiovascular disorders (CVD), osteoporosis, and spinal cord injury.

The increasing prevalence of chronic medical conditions and genetic disorders across the world is one of the key factors driving the market growth. In addition, increasing geriatric population, prone to various musculoskeletal, oncological, dermatological and cardiological disorders, is driving the growth of the market. Meanwhile, the widespread adoption of organ transplantation is also helping in the growth of the market. Regenerative medicine minimizes the risk of organ rejection by the body after transplantation and improves the speed of patient recovery. In addition, various technological advancements in cell therapy, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative drugs, act as other growth factors. These advancements also help lead effective dermatologic transplant procedures to treat chronic burns, bone defects, and wounds on the skin. Other factors, including extensive research and development (R&D) activities in medical sciences, as well as improved healthcare infrastructure, are expected to further drive the market.

Competitive landscape

The report also analyzed the competitive landscape of the market with some of the major players being Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc) and Thermo Fisher Scientific Inc.

Key questions answered in this report

  • How has the global regenerative medicine market performed so far and how will it perform in the years to come?
  • What has been the impact of COVID-19 on the global regenerative medicine market?
  • What are the main regional markets?
  • What is the market breakdown according to type?
  • What is the market split depending on the application?
  • What is the distribution of the market according to the end user?
  • What are the different stages of the industry value chain?
  • What are the main factors and challenges for the industry?
  • What is the structure of the global regenerative medicine market and who are the major players?
  • How competitive is the industry?

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Regenerative Medicine Market
5.1 Market overview
5.2 Market performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market breakdown by type
6.1 Stem cell therapy
6.1.1 Market trends
6.1.2 Market Forecast
6.2 Biomaterial
6.2.1 Market trends
6.2.2 Market Forecast
6.3 Tissue engineering
6.3.1 Market trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market trends
6.4.2 Market Forecast

7 Market split by application
7.1 Bone graft substitutes
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Osteoarticular diseases
7.2.1 Market trends
7.2.2 Market Forecast
7.3 Dermatology
7.3.1 Market trends
7.3.2 Market Forecast
7.4 Cardiovascular
7.4.1 Market trends
7.4.2 Market Forecast
7.5 Central nervous system
7.5.1 Market trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market trends
7.6.2 Market Forecast

8 Market breakdown by end user
8.1 Hospitals
8.1.1 Market trends
8.1.2 Market Forecast
8.2 Specialized clinics
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market trends
8.3.2 Market Forecast

9 Market breakdown by region

10 SWOT Analysis

11 Value chain analysis

Analysis of the five forces of 12 carriers

13 Price analysis

14 Competitive landscape
14.1 Market structure
14.2 Key players
14.3 Profiles of key players
14.3.1 Allergan PLC (AbbVie Inc.)
14.3.1.1 Company presentation
14.3.1.2 Product portfolio
14.3.1.3 Finances
14.3.1.4 SWOT Analysis
14.3.2 Amgen Inc.
14.3.2.1 Company overview
14.3.2.2 Product portfolio
14.3.2.3 Finances
14.3.2.4 SWOT Analysis
14.3.3 Baxter International Inc.
14.3.3.1 Company overview
14.3.3.2 Product portfolio
14.3.3.3 Finances
14.3.3.4 SWOT Analysis
14.3.4 BD (Becton, Dickinson and company)
14.3.4.1 Company overview
14.3.4.2 Product portfolio
14.3.4.3 Finances
14.3.4.4 SWOT Analysis
14.3.5 Integra Lifesciences Holding Company
14.3.5.1 Company overview
14.3.5.2 Product portfolio
14.3.5.3 Finances
14.3.5.4 SWOT Analysis
14.3.6 Medtronic API
14.3.6.1 Company overview
14.3.6.2 Product portfolio
14.3.6.3 Finances
14.3.6.4 SWOT Analysis
14.3.7 Mimedx Group inc.
14.3.7.1 Company overview
14.3.7.2 Product portfolio
14.3.7.3 Finances
14.3.8 Novartis AG
14.3.8.1 Company overview
14.3.8.2 Product portfolio
14.3.8.3 Finances
14.3.8.4 SWOT Analysis
14.3.9 Osiris Therapeutics Inc. (Smith & Nephew PLC)
14.3.9.1 Company overview
14.3.9.2 Product portfolio
14.3.10 Thermo Fisher Scientific Inc.
14.3.10.1 Company overview
14.3.10.2 Product portfolio
14.3.10.3 Finances
14.3.10.4 SWOT Analysis

For more information on this report, visit https://www.researchandmarkets.com/r/bij9yq

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com


Source link

Leave A Reply

Your email address will not be published.